Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Liuwei Dihuang Glycoside Tablet is a refined botanical drug candidate developed by the Institute of Toxicology and Pharmacology at the Academy of Military Medical Sciences (AMMS) in China. It is a purified formulation derived from the classic Liuwei Dihuang formula, a cornerstone of Traditional Chinese Medicine (TCM) used to treat Kidney Yin Deficiency. The tablet contains standardized active fractions, primarily glycosides and polysaccharides (often referred to in research as LW-AFC), extracted from six herbs: Rehmannia glutinosa, Cornus officinalis, Paeonia suffruticosa, Dioscorea opposita, Poria cocos, and Alisma orientale. It is specifically being developed for the treatment of menopausal syndrome, where it is thought to modulate the hypothalamic-pituitary-ovarian (HPO) axis and exert estrogen-like effects to alleviate symptoms such as hot flashes and mood disturbances. Clinical trials, including Phase 2 dose-response studies, have utilized the modified Kupperman scale to evaluate its efficacy compared to traditional Liuwei Dihuang pills and placebo.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on liuwei dihuang glycoside tablet.